First‐in‐Human (FIH), Single‐ and Multiple‐Ascending‐Dose (SAD/MAD) studies in healthy subjects of E2511, a novel tropomyosin receptor kinase a (TrkA) positive allosteric modulator (PAM)

نویسندگان

چکیده

Background Cholinergic innervation is affected in multiple neurodegenerative diseases associated with cognitive dysfunction. Loss of cholinergic neurons Alzheimer’s disease (AD) correlated impairment. Nerve growth factor (NGF) plays a major role the maintenance and function neurons. The activation NGF-induced trophic signaling via TrkA could be promising therapy for including AD. E2511 novel small molecule biased PAM that has shown reinnervative effects on nonclinical studies (without NGF-associated hyperalgesia). main objectives FIH Phase 1 (SAD [completed] MAD [ongoing]) are to evaluate safety, tolerability pharmacokinetics healthy subjects. Methods : Both SAD randomized, double-blind placebo-controlled studies. evaluated 5 cohorts (n = 8/cohort) adults cohort elderly subjects 5). Food effect was one cohort. Safety through review adverse events, physical examinations, clinical laboratory tests, vital signs, electrocardiogram electroencephalograms. Blood samples were collected determination plasma concentrations. Repeat dosing (once daily 14 days) under evaluation study. Results Single doses safe well-tolerated across investigated adult There no dose-dependent nor severe treatment-emergent events (TEAEs). clinically significant changes safety parameters compared placebo. Pharmacokinetic results show rapidly absorbed (tmax: hour). Plasma half-life 3.2 hours. exposures (Cmax AUC) increased dose proportionally over range. led decrease 19% Cmax 15% AUC fasted conditions. younger comparable. Evaluation PK/PD following ongoing. Conclusion presented an adequate PK profile These support further development as disease-modifying diseases.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Docking Studies of Benzodiazepines as a Positive Allosteric Modulator of Gaba-a Receptor

Benzodiazepine is an antixylotic agent , induce and maintain sleep, reduce seizures, and induce conscious sedation. It acts as a positive allosteric modulator of GABAA receptor. The binding of benzodiazepine analogues to this allosteric modulatory site enhances the affinity of GABA (Gama amino butyric acid) for the agonist recognition site. In the present work, docking studies has been performe...

متن کامل

Neurophysiologic and antipsychotic profiles of TASP0433864, a novel positive allosteric modulator of metabotropic glutamate 2 receptor.

Excess glutamatergic neurotransmission has been implicated in the pathophysiology of schizophrenia, and the activation of metabotropic glutamate 2 (mGlu2) receptor may exert antipsychotic effects by normalizing glutamate transmission. In the present study, we investigated the neurophysiologic and antipsychotic profiles of TASP0433864 [(2S)-2-[(4-tert-butylphenoxy)methyl]-5-methyl-2,3-dihydroimi...

متن کامل

Characterization of RO 5126946 , a Novel a 7 Nicotinic Acetylcholine Receptor – Positive Allosteric Modulator s

Both preclinical evidence and clinical evidence suggest that a7 nicotinic acetylcholine receptor activation (a7nAChR) improves cognitive function, the decline of which is associated with conditions such as Alzheimer’s disease and schizophrenia. Moreover, allosteric modulation of a7nAChR is an emerging therapeutic strategy in an attempt to avoid the rapid desensitization properties associated wi...

متن کامل

Ignavine: a novel allosteric modulator of the μ opioid receptor

Processed Aconiti tuber (PAT) is used to treat pain associated with various disorders. Although it has been demonstrated that the κ opioid receptor (KOR) signaling pathway is a mediator of the analgesic effect of PAT, active components affecting opioid signaling have not yet been identified. In this study, we explored candidate components of PAT by pharmacokinetic analysis and identified ignavi...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Alzheimers & Dementia

سال: 2023

ISSN: ['1552-5260', '1552-5279']

DOI: https://doi.org/10.1002/alz.066208